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Abstract
Background: Niemann-Pick disease type C (NPC) is an inherited metabolic disorder; due to defect in cellular cholesterol
trafficking. It is clinically a heterogeneous disease with variable age of onset with multiple organ systems being involved.
NPC1 gene is involved in 95% cases where as remaining ~5% cases are linked with NPC2 gene.
Case presentation: Case-1, a 14-months-old female presented with recurrent respiratory distress, failure to thrive and
hepatosplenomegaly. Lung biopsy was suggestive of alveolar proteinosis and liver biopsy confirmed foamy macrophages.
Molecular analysis revealed homozygous mutation c.141C > A in exon 2 of NPC2 gene.
Case-2, a 3-year-old male presented with dyspnoea and hepatomegaly noticed at 1 year of age. HRCT-scan of thoracic
region showed consolidation with mediastinal lymphadenopathy. Broncho-alveolar lavage revealed moderate amount of
foamy macrophages and bone marrow examination detected foam cells. Homozygous T > C transition in intron 1 of the
NPC2 gene was identified.
Conclusion: Our study demonstrates that NPC2 can present in early years of life with pulmonary complications like
alveolar proteinosis and hepatosplenomegaly or hepatomegaly due to mutation in NPC2 gene. An early suspicion will
help clinicians to clinch its diagnosis, management and genetic counselling.
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Background
Niemann–Pick disease type C (NPC) is a fatal autosomal
recessive neurovisceral disorder due to mutation in NPC1
and NPC2 genes leading to alterations in trafficking of
endocytosed cholesterol [1]. Due to heterogeneous clinical
phenotype, NPC is underdiagnosed and often missed
altogether. In NPC, the protein product of the NPC1 gene
functions as a transporter of cholesterol and glycolipids in
the endosomal-lysosomal system whereas the smaller
protein product of NPC2 cooperates with the NPC1
protein [2, 3]. NPC2 plays a vital role in endosomal/
lysosomal cholesterol trafficking by markedly accelerating
the rates of transport from and between membranes [4].
The mechanism of NPC2 action involves direct inter-
action of the protein with membranes. The defects in
NPC1 and NPC2 proteins, leads to sequestration of
cholesterol derived products in the cell leading to hepatos-
plenomegaly, pulmonary and neurological manifestations
[3]. NPC1 gene is responsible for 95% of manifestations
with main phenotype being hepatosplenomegaly and
nervous system. The other ~5% of the NPC is caused
by NPC2 gene where pulmonary manifestations with
respiratory failure have been documented [5]. Till date
nearly twenty cases have been reported of NPC2 with
twelve homoallelic mutations and none from India.
Present study is the first report of NPC2 from India with
primary pulmonary manifestations and hepatosplenome-
galy highlighting phenotype-genotype correlation.
Case presentation
Case-1: 9 month old female child born to non-
consanguineous parents from Rajasthan (Marwadi
community) presented with recurrent respiratory tract
infection and failure to thrive. She was frequently
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hospitalized for tachypnea and developed hepatosple-
nomegaly in next 5 months. Multiple treatment mo-
dalities were tried including antibiotics, nebulisations,
anti-fungal agents, systemic corticosteroids and moist
oxygen inhalation. In spite of all these, child remained
tachypneic and continued to be oxygen dependent.
Her chest radiogram showed hazy, diffuse bilateral
alveolar infiltrates. HRCT showed ground glass opaci-
fication of the right upper lobe, suggestive of alveolar
proteinosis. Lung biopsy with PAS staining showed
dilated alveoli, lined by type-2 pneumocytes, containing
foamy macrophages further indicating alveolar proteinosis.
Possibility of a secondary alveolar proteinosis was kept in
view of hepatosplenomegaly along with lung involvement.
Liver biopsy showed fairly well preserved lobular architec-
ture and cord pattern, few lymphocytes in portal tract and
finely vacuolated ballooned hepatocytes and kupffer cell
were suggestive of Niemann-Pick disease. Further studies
revealed high plasma chitotriosidase level with fifty
percent reduced activity of acid Sphingomyelinase
[3.6 nmol/hr/mg – NR: 8.0-14.5 nmol/hr/mg protein].
This has clinched the clinical suspicion of NPC in the
proband. Infilatration of the lungs with liver disease in
the proband pointed towards NPC2 diagnosis. There-
fore bi-directional sanger sequencing covering exon-
intron boundries of NPC2 gene was carried out. This
has identified homozygous nonsense variant (c.141C >A)
(p.Cys47Ter) in exon 2 (Fig. 1a). This variant is re-
ported as pathogenic in HGMD (CM052291) and
ClinVar (dbSNP80358263) database and responsible
for protein truncation (variation ontology:0015).
Case-2: 1 year old male child born to third degree
consanguineous parents from Maharshtra (Brahmin
community) presented with dyspnoea, hepatomegaly
and failure to thrive. Limbs were hypotonic with normal
reflexes and power. Chest X-rays showed hyperinflation
initially and progressive perihilar alveolar infiltration
sparing peripheries. HRCT scan of thoracic region
showed patchy alveolar fibrosis with mediastinal lymph-
adenopathy. Broncho-alveolar lavage revealed moderate
amount of foamy macrophages and bone marrow
examination showed presence of foamy histiocytic
cells. Enzyme study for Niemann Pick type A, B and
Gaucher’s disease were normal. Since acid sphingo-
myelinase was normal and pulmonary manifestations
and hepatomegaly were predominantly present, NPC
was suspected. Further study was carried out by bi-
directional Sanger sequencing of NPC2 gene covering
exon-intron boundries. This has identified homozy-
gous splice site variation c.82 + 2 T > C (g.5191 T > C)
in NPC2 gene (Fig. 1b). This variant is reported as
pathogenic in HGMD (CS032706) and ClinVar
(dbSNP:879253740) database that affect RNA splicing
(variation ontology:0362).
Discussion
NPC is a rare neurovisceral disease with an overall inci-
dence of 1:150,000, of which only 5% cases are linked to
NPC2 [6]. It is caused due to deposition of unesterified
cholesterol mainly in brain, liver and lungs. Primary
diagnosis of NPC by filipin stain is considered as the
gold standard [7]. However, being tedious and time con-
suming, molecular testing was introduced in 2000 where
the molecular defect was detected in NPC1 and NPC2
gene located on chromosome 18q11.2 and 14q24.3 re-
spectively [3]. Since then several studies have shown
an association of pulmonary manifestation and hepa-
tosplenomegaly with NPC2 [8–11]. Likewise the two
cases under study had a similar clinical presentation
and were investigated primarily for acid sphingomyeli-
nase (aSMase) activity in leucocytes. Case 1 had
shown nearly 50% reduced activity of sphingomyeli-
nase while case 2 had shown normal activity. Nearly
fifty percent reduced activity of spingomyelinase in
case 1 can be due to gross disruption of sphingomyeli-
nase processing by intracellular cholesterol loading
affecting aSMase activity as has been shown in CHO
cell lines [12]. Pulmonary phenotype with reduced aSMase
activity gave a clue of NPC2 in case 1. Identical phenotype
led to consideration of NPC2 in the second case. Molecu-
lar study has identified previously known pathogenic non
sense and RNA splicing mutations respectively. Both
NPC2 mutations are known to be associated with pul-
monary manifestations which may be a result of loss of
normal NPC2 protein expression in alveolar macrophages
leading to an accumulation of functionally inactive surfac-
tant rich in cholesterol [11].
In absence of specific biomarkers for NPC2, non-
enzymatic plasma levels of certain cholesterol oxidation
products (oxysterols) can be used for clinical screening of
NPC. However, this screening method alone cannot dis-
tinguish between causative gene NPC1 from NPC2 [13].
NPC1 and NPC2 carrying mutants are identical in
terms of pathogenesis and clinical phenotype/s but there
lies a discrete demarcation where pulmonary manifesta-
tions give clue to the diagnosis of NPC2 gene [14]. Iden-
tification of NPC2 as the causative factor for NPC with
pulmonary involvement was shown by Park et al. for the
first time in 2003 [15]. Moreover, three mutations in the
NPC2 gene were subsequently notified by Verot et al. in
2007 [16]. In 2005, Chikh et al. demonstrated that
missense mutation of NPC2 causes misfolding of
endoplasmic reticulum proteins [17].
A detailed clinical analysis and mutation in NPC2
have clearly shown pronounced lung involvement as a
cause of early death in six patients as shown by Millat
et al. and several others [18–20]. Similar severity was
observed in the present cases. Till date, nearly twenty
patients with twelve different homoallelic mutations in
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NPC2 gene with pulmonary manifestations have been
reported (Fig. 2, Table 1) [20, 21]. Documentation of
these mutations with phenotypic presentation has
become obligatory as commonly occurring bronchitis/
pneumonia with liver involvement and failure to thrive
are likely to mimic NPC2. Our study emphasizes the
association of homoallelic mutation of NPC2 gene
with non responsive alveolar fibrosis/proteinosis and
hepatomegaly.
Reporting more cases of NPC2 having pulmonary pheno-
type will help the clinicians to reach at an early diagnosis
and counselling to the family for possible therapeutic
options. Though Miglustat therapy is known to be useful
for NPC disease with neurological disease but not with
pulmonary manifestations [22] successful allogeneic bone
marrow transplant [23] was performed in one patient with
NPC2 and may be helpful in further patients once early
diagnosis is clinched.
Fig. 1 Sequencing of the NPC genes. a Chromatogram showing homozygous nonsense mutation c.141C > A (p.C47X) in exon 2 of NPC2. b
Homozygous intronic c.82 + 2 T > C transition mutation detection in intron 1 of NPC2
Fig. 2 Schematic view of mutations reported in NPC2 gene having pulmonary manifestation. Mutations observed in the present study are shown
in bold
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Conclusion
Mutations in NPC2 gene were studied for the first
time in Indian subcontinent and rarely been reported
in the literature. Accurate recognition of young patients
with primary unexplained alveolar fibrosis/proteinosis to-
gether with hepatomegaly suggesting NPC with molecular
characterization of NPC2 gene is essential. This will pro-
vide important new information about functional domains
of NPC2 and advance the understanding of its precise
function and its potential interactions with NPC1. More-
over, it will enhance our knowledge regarding the under-
lying pathogenic mechanism responsible for pulmonary
manifestation.
Abbreviation
HRCT-scan: High Resolution Computer Tomography Scan; NPC: Niemann–Pick
disease type C; OPD: Out Patient Department; PAS: Periodic Acid Schiff
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